Examinando por Materia "Zika virus"
Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
Publicación Acceso abierto Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection(Estados Unidos: Journal of Clinical Microbiology,2018., 2019-09-19) Lakshmanane, Premkumar; Collins, Matthew; Graham, Stephen; Liou, Guei-Jiun Alice; Camacho, ErwinZika virus (ZIKV) is an emerging flavivirus that can cause birth defects and neurologic complications. Molecular tests are effective for diagnosing acute ZIKV infection, although the majority of infections produce no symptoms at all or present after the narrow window in which molecular diagnostics are dependable. Serology is a reliable method for detecting infections after the viremic period; however, most serological assays have limited specificity due to cross-reactive antibodies elicited by flavivirus infections. Since ZIKV and dengue virus (DENV) widely cocirculate, distinguishing ZIKV infection from DENV infection is particularly important for diagnosing individual cases or for surveillance to coordinate public health responses.Publicación Acceso abierto Zika virus like particles elicit protective antibodies in mice.(California, Estados Unidos: PLoS Neglected Tropical Diseases , 2018., 2019-10-29) Salvo, Mauricio A; Kingstad Bakke, Brock; Salas Quinchucua, Cristhian; Camacho, Erwin; Osorio, Jorge E.Mosquito-borne Zika virus (ZIKV) typically causes a mild and self-limiting illness known as Zika fever. Since its recent emergence in 2014 in the American continent, ZIKV infection during pregnancy has been closely associated with a wide range of congenital abnormalities. To date, no vaccines or antivirals are publicly available. We developed Zika virus-like particles (VLPs) and evaluated their immunogenicity and protective efficacy in mouse models. ZIKV VLPs (ZIKVLPs) formulated with alum were injected into 6-8-week-old interferon deficient AG129 mice as well as wild type BALB/c mice. Control mice received PBS/alum. Animals were challenged with 200 PFU (>1000 AG129 LD50s) of ZIKV strain H/PF/2013. All vaccinated mice survived with no morbidity or weight loss while control animals either died at 9 days post challenge (AG129) or had increased viremia (BALB/c). Neutralizing antibodies were observed in all ZIKVLP vaccinated mice. The role of neutralizing antibodies in protecting mice was demonstrated by passive transfer. Our findings demonstrate the protective efficacy of the ZIKVLP vaccine and highlight the important role that neutralizing antibodies play in protection against ZIKV infection.